AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox


Summary
• Price edged higher, forming bullish engulfing and inside bars near $0.043.
• RSI signaled overbought conditions near 70, while MACD showed flattening momentum.
• Volatility dipped slightly in late ET hours but remained within Bollinger Band boundaries.
At 12:00 ET − 1, BIOUSDT opened at $0.0426, reached a high of $0.0435, and a low of $0.0416 before closing at $0.043 at 12:00 ET. Total 24-hour volume was 43.4 million units, with turnover of $1.87 million.
Structure & Formations
Price action over the 24-hour period showed a clear bullish tilt, with a notable breakout above $0.043 after an extended consolidation phase. Engulfing patterns formed near $0.0431–0.0432, suggesting short-term buyers stepped in aggressively.

Technical Indicators
The RSI approached overbought territory near 70 in the last few hours, signaling a potential pullback. MACD remained positive but showed a narrowing histogram, suggesting buyers may be losing steam. Volatility, as measured by Bollinger Bands, remained relatively tight until late ET, after which price moved into the upper band, indicating a breakout in progress.
Volume & Turnover
Turnover spiked to a 24-hour peak near $0.0432, coinciding with a bullish reversal pattern. Notional turnover increased steadily in the final 6–8 hours, aligning with price higher highs. The absence of divergence between price and volume suggests the bullish trend has strong legs, though caution is warranted if volume fails to expand further in the next 24 hours.
Bio Protocol/Tether appears to be consolidating after a sharp rally, with strong support intact and key resistance levels in view. A break above $0.0435 could target $0.0437–0.0440, but buyers may face testing in the next 24 hours if the RSI overbought level is not respected.
Decoding market patterns and unlocking profitable trading strategies in the crypto space

Dec.20 2025

Dec.20 2025

Dec.20 2025

Dec.20 2025

Dec.20 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet